These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. Lu JJ, Crimin K, Goodwin JT, Crivori P, Orrenius C, Xing L, Tandler PJ, Vidmar TJ, Amore BM, Wilson AG, Stouten PF, Burton PS. J Med Chem; 2004 Nov 18; 47(24):6104-7. PubMed ID: 15537364 [Abstract] [Full Text] [Related]
4. Design and Development of a Cyclic Decapeptide Scaffold with Suitable Properties for Bioavailability and Oral Exposure. Fouché M, Schäfer M, Berghausen J, Desrayaud S, Blatter M, Piéchon P, Dix I, Martin Garcia A, Roth HJ. ChemMedChem; 2016 May 19; 11(10):1048-59. PubMed ID: 27154275 [Abstract] [Full Text] [Related]
5. Time-related differences in the physical property profiles of oral drugs. Leeson PD, Davis AM. J Med Chem; 2004 Dec 02; 47(25):6338-48. PubMed ID: 15566303 [Abstract] [Full Text] [Related]
6. Selecting the right compounds for screening: does Lipinski's Rule of 5 for pharmaceuticals apply to agrochemicals? Tice CM. Pest Manag Sci; 2001 Jan 02; 57(1):3-16. PubMed ID: 11455629 [Abstract] [Full Text] [Related]
14. Predicting the Drug Clearance Pathway with Structural Descriptors. Kaboudi N, Shayanfar A. Eur J Drug Metab Pharmacokinet; 2022 May 28; 47(3):363-369. PubMed ID: 35147854 [Abstract] [Full Text] [Related]
15. Pharmacokinetics and metabolism of 4-O-methylhonokiol in rats. Yu HE, Oh SJ, Ryu JK, Kang JS, Hong JT, Jung JK, Han SB, Seo SY, Kim YH, Park SK, Kim HM, Lee K. Phytother Res; 2014 Apr 28; 28(4):568-78. PubMed ID: 23824979 [Abstract] [Full Text] [Related]
16. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. Wager TT, Hou X, Verhoest PR, Villalobos A. ACS Chem Neurosci; 2010 Jun 16; 1(6):435-49. PubMed ID: 22778837 [Abstract] [Full Text] [Related]
17. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Kamath AV, Wang J, Lee FY, Marathe PH. Cancer Chemother Pharmacol; 2008 Mar 16; 61(3):365-76. PubMed ID: 17429625 [Abstract] [Full Text] [Related]
18. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH. Cancer Chemother Pharmacol; 2005 Aug 16; 56(2):145-53. PubMed ID: 15830240 [Abstract] [Full Text] [Related]
19. Characteristic physical properties and structural fragments of marketed oral drugs. Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, Durst GL, Hipskind PA. J Med Chem; 2004 Jan 01; 47(1):224-32. PubMed ID: 14695836 [Abstract] [Full Text] [Related]
20. Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. Li Z, Han X, Zhai Y, Lian H, Zhang D, Zhang W, Wang Y, He Z, Liu Z, Sun J. Colloids Surf B Biointerfaces; 2015 Jun 01; 130():133-40. PubMed ID: 25907597 [Abstract] [Full Text] [Related] Page: [Next] [New Search]